|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said it will to delay the development of ALN-VEG01, its vascular endothelial growth factor (VEGF)-targeting drug to treat age-related macular degeneration. President and CEO John Maraganore attributed the decision to an "increasingly competitive landscape for VEGF-targeting AMD therapeutics on the market and in late-stage human trials." Instead, the company plans to allocate its resources to advancing ALN-RSV01, an RNAi therapeutic candidate for treating respiratory syncytial virus infection. Alnylam now plans to file an investigational new drug application for ALN-RSV01 by the end of the year, rather than during the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Former cult member, San Diego County officials ...
Knight Ridder/Tribune News Service;
April 16, 1997 ;
700+ words
... ... toward the next level: Mass marketing of a mass suicide. Movie negotiations ... Web site. And now, as San Diego County officials sift ... tragedy.'' Meanwhile, San Diego County officials are ... over their heads. As mass suicides go, it had ...
|
|